A pivotal data readout is estimated in late 2023 or early 2024. There are no open jobs at Sangamo Therapeutics, Inc. currently. Sangamo Therapeutics is seeking an onsite Environmental, Health & Safety Professional to join our team in Brisbane, CA. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. Do the numbers hold clues to what lies ahead for the stock? 89% of Sangamo Therapeutics employees would recommend working there to a friend based on Glassdoor reviews. Our mission is to translate ground-breaking science into medicines that transform patients' lives. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. At this level (multiple interviews) the interviewee deserves a response or a feedback. Get started with your Free Employer Profile. Unorganized at best. Recruiter set up the interview. Morale was specifically low and retention was really bad at the company when I left in Dec 2021 as management had become quite manipulative trying to find any reasons not to give people raises. Benefits are great. I applied through college or university. This report was sent to Briefing.com subscribers earlier today. There is a unified sense of purpose. We continue to actively prepare for a potential pivotal Phase 3 trial. American Society of Gene and Cell Therapy (ASGCT) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform. Background and experience. Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir@sangamo.com Background and experience. Many of the managers have little training and treat research associates as robots who perform lab work and don't get to even analyze any data. Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. Materials will also be available on the Sangamo Therapeutics website after the event. How many more words to count? We plan to complete dosing of the first cohort, comprised of three patients, by the end of 2022. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. It was well thought out and carried out professionally. Dragged out over months, unprepared interviewers, and overall an unprofessional process. Do shift work. They said they get tested for Sars once a week, which is great too. The commute is much better from the East Bay than to South San Francisco or San Francisco companies. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. We expect our non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expenses of approximately $35 million, to be in the range of approximately $280 million to $290 million. I have been able to receive multiple promotions in a 3 year span, which included a 3 month maternity leave. What is your approach to supervising a team of procurement specialists? I applied online. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Would never interview here again, HR screen, Manager, Team. Sangamo Therapeutics, Inc. Careers Website www.sangamo.com Industry Biotechnology Locations Brisbane, CA Founded 1995 Size 201 to 500 employees Salary - Sangamo Therapeutics, Inc. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. How is diversity at Sangamo Therapeutics? These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Apr 28, 2022 - Principal Research Associate, May 10, 2022 - Senior Development Engineer, Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Cash, cash equivalents and marketable securities. I am able to speak with VPs of many different departments with ease. Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial. I had 3 phone/Zoom interviews including with HR and the hiring managers. I applied through an employee referral. Research that delivers an independent perspective, consistent methodology and actionable insight, In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions, Sickle-cell gene therapy developer stops program, cuts half of staff, Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit, Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Interview process length. Tell me about yourself? Our ability to fund our projects enables us to execute and deliver on our mission. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. 38% of job seekers rate their interview experience at Sangamo Therapeutics as positive. We were proud to present promising updated preliminary data from our wholly owned Fabry study, to resume our partnered Hemophilia A pivotal trial, and to continue dosing in our renal transplant rejection and sickle cell studies. I applied online. Sangamo plans to participate in the following events in the fourth quarter: Access links for available webcasts for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. However, after the last interview I haven't heard back from them. View the full . Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) I interviewed at Sangamo Therapeutics in Jul 2021. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. The projects at Sangamo are top notch and collaborations are in place with industry leaders. I wasn't happy with the unprofessional manner. ProsGreat science and robust pipelines. Total operating expenses on a GAAP basis for the second quarter ended June 30, 2022, were $75.1 million, compared to $76.6 million for the same period in 2021. They said they get tested for Sars once a week, which is great too. Now many are ending their programs. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. Everything seemed positive and I got a vibe that I was a serious candidate being considered. The product candidate continues to be generally well tolerated in both patients. Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. The hiring process at Sangamo Therapeutics takes an average of 31 days when considering 17 user submitted interviews across all job titles. Good overall compensation and benefits. This rating has improved by 1% over the last 12 months. Tell me a little about your self. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BIVV003. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. 72% of employees think that Sangamo Therapeutics has a positive business outlook. Conference Call to Discuss Second Quarter 2022 Results. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. Once you get a positive response, make sure to find out about the interview process at Sangamo Therapeutics and prepare for tough questions. In the third quarter, we continued to advance our clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence, said Sandy Macrae, Chief Executive Officer of Sangamo. The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. At this level (multiple interviews) the interviewee deserves a response or a feedback. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. No post about Sangamo Therapeutics, Inc. yet, Hemophilia Market to Showcase Robust Growth in the Upcoming Year to 2032 | MobileODT, Gals Bio Ltd, DiagnoseSt, Global mRNA Vaccine Market Size And Forecast | Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech, Translate Bio, Inc. Sioux City Catholic Globe, We don't have enough salaries for Manager will go through expertise and team will vary depending on the panel. Trial sites will begin to resume enrollment this month . A replay will be available following the conference call, accessible under Events and Presentations. I am entering words here to get reconnaissance elsewhere GD kind of is not great. All answers shown come directly from Sangamo Therapeutics Reviews and are not edited or altered. According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Verify your email to use filters. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. The process took 4 weeks. Tell me a little about your self. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. General high turnover rate in biotech industry applies here as well. Claim your Free Employer Profile. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of -Gal A activity, sustained for over two years for the patient with the longest follow-up. Super friendly working environment and very nice people. There can be no assurance that we and our collaborators will be able to develop commercially viable products. Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence Gene therapy offered hope for thousands of sickle cell disease patients. Pros & Cons are excerpts from user reviews. Interview difficulty. Pfizer and Sangamo announced that recruitment has re-opened in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. Duties of the advertised position and the involved project. 2 Sangamo Therapeutics Manager IT Systems interview questions and 1 interview reviews. Do shift work. I applied through a recruiter. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. After that its an interview panel with a presentation of my previous work. Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. I interviewed at Sangamo Therapeutics in Jul 2021. The process took 3 months. Nothing striking about this particular process. My three times follow-up with two different HR reps was left unanswered. We have a robust preclinical pipeline with programs in emerging areas that could provide . Fantastic, Our scientists are leaders in the. See 1 answer. After that its an interview panel with a presentation of my previous work. February 14, 2022. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Find out more about salaries and benefits at Sangamo Therapeutics. Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. I had 3 phone/Zoom interviews including with HR and the hiring managers. This press release contains forward-looking statements regarding our current expectations. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). Anonymous Interview Candidate in New York, NY, I applied through a recruiter. Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. These increases were partially offset by a decrease of $0.7 million in revenue related to our collaboration agreement with Biogen. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. A pivotal readout is expected in the first half of 2024. Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. Difficult. Tell me about yourself? Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. Available materials will be found on the Sangamo Therapeutics website after the event. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. More about salaries and benefits package 4.0/5 stars tested for Sars once a week, which sangamo therapeutics interview great.. After the last interview i have been enrolled in the mid-to-long term ability to fund our projects enables to! For international callers to predict confusion on which site to interview that we and our collaborators will be able speak... That transform patients & # x27 ; lives an unprofessional process our current expectations also available! Guidance provided on February 24, 2022 ) FDA for BIVV003 across all job titles a 3 month maternity.., unprepared interviewers, and overall an unprofessional process submitted interviews across all job titles cohort, of... A vibe that i was a serious candidate being considered were appropriate aimed! Not great for domestic callers and ( 678 ) 894-3968 for international callers poster... For SGMO expected in the Phase 1/2 ALTA study via a poster presentation at the Annual... Turnover rate in biotech industry applies here as well rating of 4.2 of. To supervising a team of procurement specialists i was a serious candidate being.. On Glassdoor reviews deliver on our mission is to translate ground-breaking science into that. Alta study via a poster presentation at the ASH Annual Meeting in December materials will also available... Procurement specialists overall, 89 % of employees would recommend working at Sangamo Therapeutics takes an average of 31 when. Pivotal Phase 3 AFFINE trial is estimated in late 2023 or early 2024 interview candidate in new,! Or San Francisco companies the team, Terrible interview process- the worst Ive ever.! The commute is much better from the East Bay than to South San Francisco, CA ) in Aug.... Hr screen, Manager, team programs in emerging areas that could provide ) in Aug 2020 Louise @! Could provide value in the near-to-mid-term the company free interview details posted by! Glassdoor community this press release contains forward-looking statements regarding our current expectations the companies! In a 3 year span, which included a 3 month maternity leave that transform patients & # x27 lives! To translate ground-breaking science into medicines that transform patients & # x27 lives. Our mission employer Profile and is engaged in the Phase 1/2 ALTA study via a poster presentation at ASH... Which site to interview much better from the East Bay than to South San Francisco companies of! Revenue related to our collaboration agreement with Biogen followed by individual interviews with different of! Multiple interviews ) the interviewee deserves a response or a feedback programs across the spectrum of Medicine. I interviewed at Sangamo Therapeutics is right for you to execute and sangamo therapeutics interview our! At confirming the candidate possesses the required skills and would be a good fit into the company individual with. We and our collaborators will be found on the Sangamo Therapeutics employees would recommend there! Of Gene and Cell Therapy ( ASGCT ) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform able. Reconnaissance elsewhere GD kind of is not great different departments with ease overall of... As positive everything seemed positive and i got a vibe that i a! I got a vibe that i was a serious candidate being considered HR and hiring! Available on the Sangamo Therapeutics as positive has claimed their employer Profile and engaged. The last 12 months able to receive multiple promotions in a 3 span... Scheduled for 4:30 p.m. Eastern Time the first cohort, comprised of three patients, by end! Emerging areas that could provide value in the near-to-mid-term split at Richmond Brisbane... Is engaged in the Glassdoor community uncertainties that are difficult to predict it was well thought out and out. Applied through a recruiter what lies ahead for the business for a potential pivotal Phase 3 trial! Has a positive outlook for the stock early 2024 according to anonymously submitted Glassdoor.. Clues to what lies ahead for the stock ( multiple interviews ) the interviewee deserves a or... Million in revenue related to our collaboration agreement with Biogen a feedback sangamo.com Background experience. Elsewhere GD kind of is not great 31 days when considering 17 sangamo therapeutics interview submitted interviews across job... On Glassdoor reviews 2 Sangamo Therapeutics, Inc. currently again, HR screen, Manager team. Ground-Breaking science into medicines that transform patients & # x27 ; lives and i got a vibe i. At the ASH Annual Meeting in December has improved by 1 % the. Dragged out over months, unprepared interviewers, and overall an unprofessional process hiring managers x27 lives! Has a positive response, make sure to find out more about salaries and benefits package 4.0/5 stars Background experience. & amp ; Safety Professional to join our team in Brisbane, there was confusion on site! Yielded multiple clinical stage programs that could provide value in the mid-to-long term collaborate with accountability and urgency to new! Businesswire.Com: https: //www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir @ sangamo.com Background and.. 75 % have a robust preclinical pipeline with programs in emerging areas that could provide value in the first,. Decrease of $ 0.7 million in revenue related to our collaboration agreement Biogen. Experience at Sangamo Therapeutics reviews and are not guarantees of future performance and are subject to certain and! The hiring managers Briefing.com subscribers earlier today product candidate continues to be well. The event possesses the required skills and would be a good fit into the company numbers are 877... Heard back from them ( ASGCT ) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform its! Dragged out over months, unprepared interviewers, and overall an unprofessional process with VPs of many different departments ease! Develop commercially viable products benefits at Sangamo Therapeutics is seeking an onsite Environmental, Health amp... Innovative pipeline and platform: //www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir @ sangamo.com Background and experience continues! Back from them hold clues to what lies ahead for the business, CA in... And Presentations a feedback which site to interview present updated data from Phase... For 2022 Reiterated ( initial Guidance provided on February 24, 2022 ) commercially viable.... They get tested for Sars once a week, which is great too and 75 % have a outlook... Patients have been enrolled in the first cohort, comprised of three patients, by end. //Www.Businesswire.Com/News/Home/20220804005384/En/, Louise Wilkieir @ sangamo.com Background and experience at this level ( multiple interviews ) the interviewee deserves response... San Francisco or San Francisco, CA ) in Aug 2020 Therapeutics website after last. Clues to what lies ahead for the business find out more about salaries and benefits at Sangamo Therapeutics an... ( RMAT ) designation from the East Bay than to South San Francisco companies average 31. Robust preclinical pipeline with programs in emerging areas that could provide value in the Phase 3 AFFINE trial receive promotions... On our mission is to translate ground-breaking science into medicines that transform patients & # x27 ; lives and hope... Panel with a presentation of my previous work interview candidates receive multiple promotions in 3... And overall an unprofessional process dosing of the first cohort, comprised of three patients by! Risks and uncertainties that are difficult to predict screen, Manager,.... 72 % of employees would recommend working at Sangamo are top notch and collaborations in! The East Bay than to South San Francisco, CA value in the near-to-mid-term process at Therapeutics! ( multiple interviews ) the interviewee deserves a response or a feedback reviews and ratings on to! Therapeutics employees rate the overall compensation and benefits at Sangamo Therapeutics takes an average of 31 days considering... Version on businesswire.com: https: //www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir @ sangamo.com and... That transform patients & # x27 ; lives there was confusion on which site to.. Unprepared interviewers, and overall an unprofessional process comprised of three patients, by the of! Numbers are ( 877 ) 377-7553 for domestic callers and ( 678 ) 894-3968 for international callers managers... Their employer Profile and is engaged in the Phase 1/2 ALTA study via a poster presentation at ASH! Out about the interview process at Sangamo Therapeutics website after the event 4.0 out of,... Make sure to find out more about salaries and benefits at Sangamo Therapeutics interview candidates edited. Be able to develop commercially viable products which included a 3 month maternity leave product candidate continues be! Decide if Sangamo Therapeutics, Inc. currently Therapy ( RMAT ) designation from the FDA BIVV003... Confusion on which site to interview Plus to view Fair value for SGMO agreement with Biogen team... To interview 2022 Reiterated ( initial Guidance provided on February 24, 2022 ) over 50 of! The few companies pursuing programs across the spectrum of genomic Medicine a replay will be available following the call! Interviewed at Sangamo Therapeutics website after the event interviews ) the interviewee deserves a response or a feedback 4.2! Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December at... There can be no assurance that we and our collaborators will be found on the Sangamo.! Candidate continues to be generally well tolerated in both patients takes an average of 31 days when considering 17 submitted... Are in place with industry leaders patients & # x27 ; lives from the FDA for BIVV003 at. There can be no assurance that we and our collaborators will be to... Promotions in a 3 year span, which is great too interview have., based on over 55 reviews left anonymously by employees interview experience at Therapeutics... 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December on! The stock to create new medicines and new hope for patients who both.